期刊文献+

缬沙坦治疗对CHF患者心率震荡影响的研究 被引量:1

The therapeutic effects of valsartan on heart rate turbulence in patients with congestive heart failure
原文传递
导出
摘要 目的研究慢性充血性心力衰竭(CHF)病人24h动态心电图(24hDCG)恶性室性心律失常与心率震荡(HRT)的关系,以及缬沙坦干预后HRT的变化。方法选择有室性早搏的病人62例,分为CHF组(27例)和正常对照组(35例),所有病人均行24h动态心电图监测,计算心率震荡的初始值(TO)、震荡斜率(TS);CHF病人在常规治疗基础上加用缬沙坦口服1月后复查24hDCG监测。结果正常对照组TO<0,而CHF组TO>0;CHF组的TS明显低于正常对照组。CHF患者口服缬沙坦1个月前后对比,HRT有明显改善:TO下降,TS升高。结论HRT降低可以做为预测CHF恶性室性心律失常发生的指标;缬沙坦能改善CHF的自主神经功能,从而改善HRT,减少恶性室性心律失常的发生。 Objective To observe the therapeutic effect of valsartan on heart rate turbulence (HRT) in patients with congestic heart failure (CHF). Methods There 62 patients with premature ventrictdar beats were divided into CHF group consisted of 27 cases and control group consisted of 35 cases . All patients were examined with ambulatory electrocardiogram monitoring for twenty-four hours, and turbulence onset (TO) and turbulence slope (TS) were analyzed. Patients in the CHF group were given orally valsartan and anabulatory electrocardiogram monitoring was examined after a month. Results TO were 〈0 in the control group and〉0 in the CHF group. TS was higher in the control group than that of the CHF group. TO decreased and TS increased respectively after oral administration of valsartan for a month in the CHF group. Conclusion HRT is of clinical prognostic value for predicting sudden death in patients with CHF; Valsartan can improve function of autonomic nerve in CHF patients in addition to improvement of HRT and resuction of malignant ventricular arrhythmia
作者 唐通
出处 《中国热带医学》 CAS 2009年第3期503-504,共2页 China Tropical Medicine
关键词 慢性充血性心力衰竭 心率震荡 恶性室性心律失常 缬沙坦 Congestive heart failure Heart rate turbulence Malignant ventrieular arrhythmia Valsartan
  • 相关文献

参考文献6

  • 1Ribeiro AL,Schmidt G,Sousa MR,et al . Heart rate turbulence in chagas disease [J ]. Pacing Clin Electrophysiol, 2003,26(2):406.
  • 2Schmidt G,Molik M,Barthel P,et al . Heart rate turbulence after ventricular premature beats as a predictor of mortality after acute myocardial infarction [ J ]. Lancet, 1999,353(7): 1390-1396.
  • 3Skanes AC,Tand ASL . Ventriculophasic modulation of atrioventricular nodal conduction in human [J]. Circulation,1998,99 (10): 2245-2251.
  • 4Luereziotti S,Gavazzi A,Scelsi L,et al. Five-minute recording of heart rate variability in severe chronic heart failure: correlates with right ventricular function and prognostic implications [J]. Am Heart J,2000,139(6):1088.
  • 5Wagstein F . Adrenergic beta-blocking agents in congestive heart failure due to idiopathic congestive heart failure [J]. Eur Heart J, 1995,16(suppl):128.
  • 6马虹.(8)血管紧张素转换酶抑制剂、血管紧张素Ⅱ受体拮抗剂在心力衰竭治疗中的作用[J].中国循环杂志,2006,21(3):165-167. 被引量:10

二级参考文献12

  • 1The Consensus Trial Study Group. Effects of enalapril on mortality on severe congstive heart failure. N Engl J Med, 1987,316 : 1429-1435.
  • 2The SOLVD Investigators. effects of enalapril on survival in patients with reduced left ventricular ejection fractions and congestion heart failure. N Engl J Med, 1991,325:293-302.
  • 3Cohn JN, Johnson G, Ziesche S, et al. A comparison of enalapril with hydralazine-isosorbide dinitrate in the treatment of chronic congestive heart failure. N Engl J Med, 1991,325:303-310.
  • 4Pitt B, Segal R, Martinez FA, et al. Randomised trial of losartan versus captopril in patients over 65 with heart failure ( evaluation of losartan in the elderly study, ELITE ). Lancet, 1997,349:747-752.
  • 5Pitt B, Poole-Wilson PA, Segal R, et al. Effect of losartan compared with captopril on mortality in patients with symptomatic heart failure:randomized trial-the Losartan Heart Failure Survival Study ELITE Ⅱ. Lancet,2000,355 : 1582-1587.
  • 6Cohn JN ,Tognoni G. A randomized trial of the agniotensin-receptor blocker valsartan in chronic heart failure. N Engl J Med, 2001,345 : 1667-1675.
  • 7Granger CB, McMurray JJ, Yusuf S, et al. , CHARM Investigators and Committees. Effects of candesattan in patints with chronic heart failure and reduced left-ventricular systolic function intolerant to angihensin convetting-enzyme inhibitors: the CHARM-Alternative trial. Lancet, 2003,362:772-776.
  • 8McMurray JJ,Ostergren J, Swedberg K,et al. Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function taking angiotensin converting enzyme inhibitors:the CHARM-Added trial.Lancet ,2003,372:767-771.
  • 9Yusuf S, Pfeffer MA, Swedberg K, et al. CHARM Investigators and Committees. Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction:the CHARM-Preserved Trial.Lancet ,2003,362:777-781.
  • 10Pfeffer MA, Swedberg K, Granger CB, et al. CHARM Investigators and Committees. Effects of candesartan on mortality and morbidity in patients with chronic heart failure: the CHARM-Overall programme. Lancet,2003,362:759-766.

共引文献9

同被引文献9

引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部